ATE374826T1 - Chimäre polypeptide und ihre verwendung - Google Patents

Chimäre polypeptide und ihre verwendung

Info

Publication number
ATE374826T1
ATE374826T1 AT04727873T AT04727873T ATE374826T1 AT E374826 T1 ATE374826 T1 AT E374826T1 AT 04727873 T AT04727873 T AT 04727873T AT 04727873 T AT04727873 T AT 04727873T AT E374826 T1 ATE374826 T1 AT E374826T1
Authority
AT
Austria
Prior art keywords
dna
activity
activities
chimeric molecules
region
Prior art date
Application number
AT04727873T
Other languages
German (de)
English (en)
Inventor
Christian Kuehne
Andras Simoncsits
Original Assignee
Icgeb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icgeb filed Critical Icgeb
Application granted granted Critical
Publication of ATE374826T1 publication Critical patent/ATE374826T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
AT04727873T 2003-04-18 2004-04-16 Chimäre polypeptide und ihre verwendung ATE374826T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.

Publications (1)

Publication Number Publication Date
ATE374826T1 true ATE374826T1 (de) 2007-10-15

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727873T ATE374826T1 (de) 2003-04-18 2004-04-16 Chimäre polypeptide und ihre verwendung

Country Status (16)

Country Link
US (3) US20060292629A1 (enExample)
EP (1) EP1616011B1 (enExample)
JP (2) JP4794432B2 (enExample)
KR (2) KR101360781B1 (enExample)
CN (1) CN100584950C (enExample)
AT (1) ATE374826T1 (enExample)
AU (1) AU2004230254B2 (enExample)
CA (1) CA2522525A1 (enExample)
CY (1) CY1107115T1 (enExample)
DE (1) DE602004009301T2 (enExample)
DK (1) DK1616011T3 (enExample)
ES (1) ES2293247T3 (enExample)
IT (1) ITMI20030821A1 (enExample)
PL (1) PL1616011T3 (enExample)
PT (1) PT1616011E (enExample)
WO (1) WO2004092194A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
JP2008530575A (ja) * 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ Ｃｈｋ１阻害薬に対する応答性を判定する方法
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
WO2008141096A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
HK1231556A1 (zh) 2014-02-17 2017-12-22 克劳德贝尔纳里昂第一大学 确定组织放射敏感性的预测方法
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
WO2017178885A2 (en) * 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
EP4269427A3 (en) 2016-05-27 2023-11-22 Synthex, Inc. Protein interfaces
EP3469070B1 (en) * 2016-06-09 2021-08-04 Alma Mater Studiorum - Università di Bologna Herpesvirus with modified glycoprotein b
MY200418A (en) 2017-06-15 2023-12-25 Univ California Targeted non-viral dna insertions
SG11202003798TA (en) 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
AU2022409717A1 (en) 2021-12-16 2024-05-30 Pags Co., Ltd. Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
AU2982900A (en) * 1999-02-03 2000-08-25 Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
US9447434B2 (en) * 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Also Published As

Publication number Publication date
JP4794432B2 (ja) 2011-10-19
CN1768142A (zh) 2006-05-03
AU2004230254B2 (en) 2008-10-02
ITMI20030821A1 (it) 2004-10-19
KR20110074948A (ko) 2011-07-04
JP2011182792A (ja) 2011-09-22
CY1107115T1 (el) 2012-01-25
EP1616011A2 (en) 2006-01-18
WO2004092194A2 (en) 2004-10-28
US20060292629A1 (en) 2006-12-28
US20110033384A1 (en) 2011-02-10
JP2006523448A (ja) 2006-10-19
CA2522525A1 (en) 2004-10-28
CN100584950C (zh) 2010-01-27
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
DK1616011T3 (da) 2008-02-04
DE602004009301D1 (de) 2007-11-15
DE602004009301T2 (de) 2008-07-17
KR101247704B1 (ko) 2013-03-26
ES2293247T3 (es) 2008-03-16
WO2004092194A3 (en) 2005-03-17
KR20060003029A (ko) 2006-01-09
EP1616011B1 (en) 2007-10-03
US20150018409A1 (en) 2015-01-15
KR101360781B1 (ko) 2014-04-24
AU2004230254A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
DE602004009301D1 (de) Chimäre polypeptide und ihre verwendung
Passioura et al. A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets
WO2005108415A8 (en) Membrane associated molecules
EA200700408A1 (ru) Транспортный белок для доставки химических соединений в нервные клетки
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
MX2008001509A (es) Peptidos protectores de tejido y sus usos.
EP3196213A3 (en) Antibodies directed to her-3 and uses thereof
CA2345903A1 (en) Molecular pathogenicide mediated plant disease resistance
DE69937752D1 (de) Modifizierte peptide als therapeutische mittel
WO2006128668A3 (en) Coagulation factor x polypeptides with modified activation properties
TR199802252T2 (xx) N�ral ve renal geli�menin uyar�lmas� i�in ret ligand� (RetL)
Katoh et al. Ribosomal incorporation of negatively charged D-α-and N-methyl-L-α-amino acids enhanced by EF-Sep
Valeur et al. New modalities, technologies, and partnerships in probe and lead generation: enabling a mode-of-action centric paradigm
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
PL2255834T3 (pl) Projektowanie rusztowania z zastosowaniem czynników zasiedlania
Okuma et al. A Macrocyclic Peptide Library with a Structurally Constrained Cyclopropane‐containing Building Block Leads to Thiol‐independent Inhibitors of Phosphoglycerate Mutase
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
ATE342279T1 (de) Kaliumkanäle und für diese kaliumkanäle kodierende gene
WO2008094316A3 (en) Novel branchiostoma derived fluorescent proteins
WO2013162760A1 (en) Novel cyclotides with anticancer activity
DE602004018349D1 (de) MODIFIZIERTE cDNA FÜR HOHE EXPRESSIONSNIVEAUS VON FAKTOR VIII UND DESSEN DERIVATEN
WO2001085912A3 (en) Presenilin enhancers
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
Nithun et al. Advancing protein engineering via organic chemistry
WO2005062788A3 (en) Prostate specific proteins expressed in cancer and methods of use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1616011

Country of ref document: EP

EEIH Change in the person of patent owner